Nothing Special   »   [go: up one dir, main page]

Vacchi et al., 2020 - Google Patents

Tau and alpha synuclein synergistic effect in neurodegenerative diseases: When the periphery is the core

Vacchi et al., 2020

View HTML
Document ID
14029850159911104287
Author
Vacchi E
Kaelin-Lang A
Melli G
Publication year
Publication venue
International journal of molecular sciences

External Links

Snippet

In neuronal cells, tau is a microtubule-associated protein placed in axons and alpha synuclein is enriched at presynaptic terminals. They display a propensity to form pathologic aggregates, which are considered the underlying cause of Alzheimer's and Parkinson's …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Similar Documents

Publication Publication Date Title
Vacchi et al. Tau and alpha synuclein synergistic effect in neurodegenerative diseases: When the periphery is the core
Bolus et al. Modeling neurodegenerative disorders in Drosophila melanogaster
Mroczko et al. The role of protein misfolding and tau oligomers (TauOs) in Alzheimer’s disease (AD)
Schaffert et al. Do post-translational modifications influence protein aggregation in neurodegenerative diseases: a systematic review
Longhena et al. Living in promiscuity: the multiple partners of alpha-synuclein at the synapse in physiology and pathology
Rockenstein et al. Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo
Kovacs Molecular pathological classification of neurodegenerative diseases: turning towards precision medicine
Medina et al. New features about tau function and dysfunction
Bendor et al. The function of α-synuclein
Aiken et al. The α-tubulin gene TUBA1A in brain development: a key ingredient in the neuronal isotype blend
Gusella et al. Huntington's disease: seeing the pathogenic process through a genetic lens
Madsen et al. Interaction between Parkin and α-synuclein in PARK2-mediated Parkinson’s disease
Hasegawa Molecular mechanisms in the pathogenesis of Alzheimer’s disease and tauopathies-prion-like seeded aggregation and phosphorylation
Dani et al. A targeted glycan-related gene screen reveals heparan sulfate proteoglycan sulfation regulates WNT and BMP trans-synaptic signaling
Alvarez et al. Modeling Alzheimer’s disease in caenorhabditis elegans
Candelise et al. Protein aggregation landscape in neurodegenerative diseases: Clinical relevance and future applications
Hayashi et al. β-Synuclein: An enigmatic protein with diverse functionality
Tamaki et al. Molecular Dissection of TDP-43 as a Leading Cause of ALS/FTLD
Fan et al. Alpha-synuclein and cognitive decline in Parkinson disease
Oláh et al. Microtubule-associated proteins with regulatory functions by day and pathological potency at night
Ruiz-Gabarre et al. What’s in a gene? The outstanding diversity of MAPT
Olesnicky et al. Drosophila as a model for assessing the function of RNA-binding proteins during neurogenesis and neurological disease
Giong et al. Non-rodent genetic animal models for studying tauopathy: review of Drosophila, zebrafish, and C. elegans models
Carroll et al. Tau post-translational modifications: potentiators of selective vulnerability in sporadic Alzheimer’s disease
Gagliardi et al. Stathmins and motor neuron diseases: pathophysiology and therapeutic targets